Exact Sciences Corp at Citi Healthcare Conference (Virtual) Transcript
Great. Well, thank you for joining us. I'm Patrick Donnelly, the tools and diagnostics analyst here at Citi. Happy to have Jeff Elliott, CFO of Exact Sciences with us, fresh off the quarter last night, so a lot to go through with that one.
And Jeff, I guess maybe we can start from there. You guys reported, obviously, results in line with the pre-announcement, but maybe talk to the trends you saw last year and then what that flowed into in terms of kind of the 1Q guide and the full year, and then we'll kind of dive into the details, but maybe at a high level, talk through what we saw last night.
Yes. Thanks, Patrick. Great to be here. Last year, I think we ended at a very strong note. We grew Cologuard nearly 30%. We grew at Precision Oncology business also nearly 30%. And so all in, I thought good growth. The important thing here is that the pandemic appears to be abating, which is a good thing going
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
